Vera Therapeutics, Inc. VERA
32.54
(0.80)
(2.40%)
as of 25 Sep
- Market cap
- $2.4B
- P/E
- 0.0×
Follow VERA
Insider Buys
alert about insiders buying in the last 12 month
| Dec '17 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|
Current Ratio |
— | 3.36 | 22.55 | 10.73 | 4.91 | 7.71 | 25.67 | 13.64 |
Net Debt/EBITDA |
— | 0.28 | 1.03 | 2.18 | 0.98 | 1.04 | 3.37 | 2.00 |
Debt/Assets |
0.00% | 0.19% | 0.00% | 5.88% | 18.88% | 28.41% | 7.73% | 10.19% |
Debt/Equity |
— | 0.00 | 0.00 | 0.07 | 0.32 | 0.49 | 0.09 | 0.12 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
— | 0.87 | 0.65 | 0.73 | 0.76 | 0.96 | 0.89 | 0.80 |
Capex/Depreciation |
— | (0.25) | (0.17) | (28.41) | 0.07 | 0.02 | 0.12 | 0.14 |
Interest Coverage |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| — | 18.83% | 84.85% | 330.12% | (121.58%) | (107.50%) | (44.83%) | (50.71%) | |
| — | (440.59%) | (178.24%) | (47.16%) | (82.77%) | (62.54%) | (36.61%) | (43.10%) | |
ROIC |
— | (2,065.09%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
— | (304.03%) | (103.00%) | (43.57%) | (88.92%) | (64.07%) | (24.27%) | (44.27%) |
Average Days of Receivables |
— | — | 0.00 | — | — | — | — | — |
Research and Development Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
— | (35.27) | (108.91) | (2.14) | (2.55) | (2.16) | (2.45) | (3.76) |
Cash per Share |
— | 10.82 | 167.83 | 5.93 | 4.32 | 3.76 | 11.58 | 11.12 |
Shareholders Equity per Share |
— | 12.01 | 156.96 | 5.18 | 2.89 | 2.38 | 10.43 | 9.41 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | 12.01 | 156.96 | 5.18 | 2.89 | 2.38 | 10.43 | 9.41 |
Free Cash Flow |
— | (10.41) | (34.85) | (28.71) | (67.66) | (92.24) | (135.65) | (241.73) |
Working Capital |
— | 2.51 | 51.86 | 74.85 | 100.10 | 149.72 | 625.85 | 675.43 |
Capital Expenditures |
— | (0.12) | (0.04) | (5.00) | (0.06) | (0.06) | (0.97) | (0.63) |
Net Current Asset Value |
— | 1.73 | 49.94 | 68.38 | 71.17 | 98.16 | 572.69 | 598.67 |
| Other line items | ||||||||
Quick Ratio |
— | 3.01 | 22.32 | 10.36 | 4.48 | 7.21 | 25.26 | 13.37 |
Depreciation/Fixed assets |
— | 0.37 | 0.00 | 0.00 | (16.59) | (44.41) | (8.39) | (3.39) |
Cash ROIC |
— | (173.03%) | (33.49%) | (15.38%) | (31.26%) | (29.55%) | (10.69%) | (17.40%) |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Revenue per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
— | (34.84) | (108.78) | (1.76) | (2.54) | (2.16) | (2.43) | (3.75) |
Capex per Share |
— | (0.42) | (0.13) | (0.37) | 0.00 | 0.00 | (0.02) | (0.01) |
Average Payables |
— | 0.63 | 0.63 | 1.15 | 6.69 | 11.55 | 9.39 | 14.78 |
Average Assets |
— | 2.69 | 29.97 | 69.15 | 107.59 | 153.49 | 415.61 | 695.21 |
Average Common Equity |
— | (62.95) | (62.95) | (9.88) | 73.25 | 89.30 | 339.42 | 590.84 |
Capex to Sales |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Profit Margin |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates